Croatia
Croatia is the site of our European headquarters,
where Barr has manufacturing, R&D, biologic and API facilities. Croatia is the Company's second largest
European market in terms of revenues. As of the end of 2007, the Company was the leader in the Croatian
generic market with approximately 25 percent market share. Currently, the Company markets some of the
top products for the Croatian pharmaceutical market, including Sumamed (azithromycin), Klavocin
(amoxicillin clavulanic acid), Voltaren (diclofenac) and Peptoran (ranitidine). The Croatian market
is a strong branded generic market, in which substitution at the pharmacy level is generally not allowed.
Physicians represent the key decision makers in this market, making product detailing of great importance.
Croatia currently has a reimbursement system based on two independent product lists, one where essential
drugs are fully reimbursed, and a second where other select drugs are partially reimbursed.
Product Guide 
